Nucleic Acid Delivery

RNAi, pDNA Transfection Reagents for Your R&D Activity


We developed broadly acting transfection reagents to modify cells with plasmid DNA and siRNA. The transfection reagents have been optimized for the following cell models and applications:

Cell Lines in Culture:

  • kidney cells (293T)
  • breast cancer cells (MDA-MB-231, MDA-MB-435, MDA-MB-436)
  • chronic myeloid leukemia cells (K562)
  • acute myeloid leukemia cells (THP-1, KG1, SUM-149PT, MCF-7)
  • acute lymphocytic leukemia cells (NALM-6 and MOLM-13)
  • lymphoma cells (U937)
  • Primary Cells in Culture:

  • primary leukocytes
  • fibroblasts
  • vascular smooth muscle cells
  • endothelial cells
  • mesenchymal stem cells (human and rodent derived)
  • systemic and local injection of nucleic acids (siRNA)
  • local injection of nucleic acids (pDNA)
  • Animal models:

  • systemic and local injection of nucleic acids (siRNA)
  • local injection of nucleic acids (pDNA)
  • For a classification our transfection reagents by cells type please see our Transfection Reagent Selection Guide. For a detailed description of our transfection reagents please see below: Once you decide the right transfection reagent for your application, please proceed to our Store to place an order, or request a sample of our product.

    Nucleic Acid Delivery

    Nucleic Acid Delivery

    ALL-Fect

    Designed as a siRNA pDNA transfection reagent it can be used for either siRNA knockdown, plasmid DNA transformation or siRNA pDNA co-delivery. It is particularly suitable for mesenchymal stem cells from cord blood and bone marrow, and highly differentiated cells such as smooth muscle cells, and endothelial cells.

    Download Infomation ALL-Fect Brochure
    Go to Store View Product
    Benefits of the reagent :
    • High transfection efficiency
      Provides 2 to 3-fold higher efficacy in the presences of serum
    • Simple Protocol
      No need to change tissue culture medium during transfection
    • Toxicity
      Less toxic compared to commercial transfection reagents, leading to better retention of normal cellular physiology
    References :
    • Hsu and Uludağ. Biomaterials (2012) 33: 7834-7848.
    • Remant Bahadur et al., J. Materials Chemistry B (2015) 3: 3972-3982.
    • Wang et al., J. Surgical Research (2013) 183: 8-17.


    Typical performance of All-Fect for transfecting cord-blood derived mesenchymal stem cells with a GFP plasmid. The study compared the performance of All-Fect against a leading lipofection reagent under conditions optimized for each reagent. The extent of transgene expression was quantitated by flow cytometry, based on the extent of EGFP expression in arbitrary units. Typical fluorescent micrographs showing GFP expression after transfection are provided on the top.

    Prime-Fect

    This product is designed for transfection of primary cells with plasmid DNA. Prime-Fect has been tailored for attachment dependant cell plasmid DNA delivery, but also has been effective in siRNA delivery to attachment dependant cells and plasmid transfection of non-attachment dependant cells.

    Download Information Prime-Fect Brochure
    Go to Store View Prime-Fect
    Benefits of the reagent :
    • High transfection efficiency on primary cells
      Provides 2 to 3-fold higher efficacy in the presences of serum
    • Simple Protocol
      No need to change tissue culture medium during transfection
    • Toxicity
      Less toxic compared to lipofection reagents, leading to minimal alteration of cell physiology
    References :
    • KC et al., J. Materials Chemistry B (2015) 3: 3972-3982.


    Transfecting bone marrow stromal cells with Prime-Fect. GFP expression was induced with a plasmid and analyzed by fluorescent microscopy 2 days after transfection. Cell-associated DNA is visualized with a red label (A). Transfecting breast cancer MDA-MB-231 and MCF-7 cells with siRNA using Prime-Fect. The expression levels of two target genes were analyzed by qPCR after delivery of control (scrambled) and gene-specific siRNAs (2 days after transfection) (B). Transfecting umbilical cord-derived mesenchymal stem cells with Prime-Fect. GFP expression was induced with a plasmid DNA and analyzed by fluorescent microscopy 2 days after transfection. (C) A leading polymeric transfection reagent and (D) Prime-Fect.>

    Leu-Fect A & B

    These products are designed for transfection of attachment-independent (suspension growing) cells and are specifically tailored for siRNA delivery. We offer two different formulations (Leu-Fect A and Leu Fect B) that are effective in different types of attachment-independent cells. We recommend the users to test the efficacy of both reagents in their particular cell type and choose the right formulation for long-term use.

    Download Information Leu-Fect A Brochure
    Leu-Fect B Brochure
    Go to Store View Leu-Fect
    Benefits of the reagent :
    • High transfection efficiency
      Provides 2 to 3-fold higher efficacy in the presences of serum
    • Simple Protocol
      No need to change tissue culture medium during transfection
    • Toxicity
      Less toxic compared to lipofection reagents, leading to minimal alteration of cell physiology
    References :
    • Gul-Uludag et al. Leukemia Research (2014) 38: 1299–1308.
    • Landry et al. J. Controlled Release (2016) 224: 8-21.
    • Valencia-Serna et al. J. Controlled Release (2013) 172: 495-503.



    Uptake of Leu-Fect/FAM-siRNA complexes in K562 cells in vitro (A) and in vivo K562 tumors (B). Typical performance of Leu-Fect for transfecting K562 chronic myeloid leukemia (CML) cells with a specific siRNA against Bcr-Abl. The study compared the performance of Leu-Fect against a leading lipofection reagent and branched PEI (PEI25; 25 kDa) under conditions optimized for each reagent. The extent of gene silencing was quantitated by qPCR (C). The functional outcome, in the form of inhibition of cell growth, was assessed by the MTT Assay and expressed relative to non-treated cells (D).

    293-Fect

    This product is designed for transfection of attachment dependent and rapidly dividing cells 293T cells with plasmid DNA. These cells are routinely transfected for small scale production of proteins/viruses for R&D purposes, as well as industrial scale production of proteins for commercial and clinical uses. This reagent is also effective with other attachment-dependent cells such as CHO cells and breast cancer MDA-MB-231 cells.

    Download Infromation 293-Fect Brochure
    Go to Store View Product
    Benefits of the reagent :
    • High transfection efficiency
      Provides 2 to 3-fold higher efficacy in the presences of serum
    • Simple Protocol
      No need to change tissue culture medium during transfection
    • Toxicity
      Less toxic compared to lipofection and polymeric reagents, leading to better protein yields from the transfected cells
    • Stability
      Long term stability at room temperature
    References :
    • Clements et al., Clinical Orthopeadics and Related Research (2009) 467: 3129-3137.
    • Naemnark et al., Molecular Pharmaceutics (2009) 6: 1798-1815.




    Typical performance of 293-Fect for transfecting attachment-dependent 293 cells with a GFP plasmid is shown in the figure. The study compared the performance of 293-Fect against a leading lipofection reagent and linear PEI (L-PEI; 44 kDa) under conditions optimized for each reagent. Typical fluorescent micrographs showing EGFP expression after transfection (A). The extent of transgene expression was quantitated by flow cytometry, based on the percentage of cells expressing the GFP gene (B) and the extent of GFP expression in arbitrary units (C).

    In Vivo DNA-Fect

    This product is designed for delivery of plasmid DNA in animal models. It is a cost-effective alternative to PEI-based reagents marketed for in vivo applications, with improved transfection efficiency. The application of current reagents is usually limited by their toxicity, which either limits the expression of the transgenes or alters the physiological response in the vicinity of the administered agents. The biocompatibility of In Vivo DNA-Fect minimally alters the cellular physiology, allowing a better response of the expressed transgenes.

    Download Information In Vivo DNA-Fect Brochure
    Go to Store View Product
    Benefits of the reagent :
    • High transfection efficiency
      Provides 2 to 3-fold higher efficacy under serum conditions
    • Simple Protocol
      Can be administered with simple formulations such as saline
    • Toxicity
      Less toxic compared to commercial transfecting reagents, leading to better protein yields from the transfected cells
    References :
    • Rose et al., Biomaterials Science (2014) 2: 833-842.
    • Rose et al., Biomaterials (2012) 33: 3363-3374.



    Typical performance of In Vivo DNA-Fect for transfecting tissues with two separate GFP plasmids at the rat subcutaneous site is shown in the figure. The study compared the performance of In Vivo DNA-Fect against branched PEI (PEI25; 25 kDa), after the corresponding complexes were implanted in gelatin sponges for 14 days. The extent of transgene expression was assessed by histology of explanted tissues, followed by the fluorescent microscopy.

    In Vivo RNA-Fect

    This product is designed for delivery of siRNA in mice tumor models. It can be directly administered into a specific site (e.g. intratumorally), or systematically (e.g. intraperitoneal, intravenous). It is a cost-effective alternative to PEI-based reagents marketed for in vivo applications. It's low toxicity allows for higher doses of nucleic acids to be administered without affecting the health of animal models.

    Download Information In Vivo RNA-Fect Brochure
    Go to Store View Product
    Benefits of the reagent :
    • High transfection efficiency
      Provides effective transfection under physiological conditions
    • Simple Protocol
      siRNA particles can be prepared in saline suitable for administration
    • Toxicity
      Less toxic compared to other commercial transfecting reagents
    References :
    • Aliabadi et al., J. Controlled Release (2013) 172: 219-228.
    • Alshamsan et al., Translational Oncology (2011) 4: 178-188.
    • Abbasi et al., Pharmaceutical Research (2011) 28: 2516-2529.


    Tumor growth profiles as a result of siRNA delivery with In Vivo RNA-Fect is shown in the figure. The tumors were left untreated, or treated with scrambled and therapeutic siRNAs formulated with the transfection reagent. Formulations injected intratumorally (A). Formulations injected intraperitoneally (B).

    Click Here For FREE SAMPLES of two of our products! Dismiss

    //]]>